Novartis Gene Therapies’ president, Chris Fox, and team are hyper-focused on newborn screenings as the pathway to helping patients. The company's initial gene therapy, Zolgensma, for SMA has treated more than 2,300 patients worldwide. Fox details what’s next on the commercialization front and shares advice with listeners about what it takes to commercialize a therapy.
|